Navigation Links
Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths

Study confirms effectiveness of widely used approach, experts say

MONDAY, Dec. 15 (HealthDay News) -- Men with locally advanced prostate cancer -- cancer that has spread beyond the wall of the prostate gland -- who undergo radiation plus long-term hormone treatment cut their risk of dying in half, a new study has found.

The addition of radiotherapy kept patients healthy much longer, the Swedish research team concluded. In fact, by adding radiotherapy, men's overall survival was increased by 10 percent with only a modest increase in the risk of radiation-related side effects.

"The study will change practice in the treatment of locally advanced or local aggressive prostate cancer," said lead researcher Dr. Anders Widmark, from the department of radiation sciences and oncology at Umeå University. "These patients should be offered the addition of local radiation treatment."

At least one American expert agreed. "This study just proves what we have suspected for a long time -- namely, that both treatments are needed to get the best results," said Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston.

The report is published in the Dec. 16 online edition of The Lancet.

In this trial, 875 men with locally advanced prostate cancer were randomly assigned to receive either the drug flutamide (Eulexin), to block androgens (male hormones), or hormone therapy along with radiation. Androgens are thought to encourage the spread of prostate cancer, so blocking their effect is a common prostate cancer treatment.

Over an average follow-up of almost eight years, 79 men who received hormone treatment alone died, compared with 37 men who received hormone treatment plus radiation, Widmark's group found.

After 10 years, 23.9 percent of the men in the hormone therapy-only group had died from prostate cancer compared with 11.9 percent of the men in the combined treatment group. In addition, death from any cause was higher in the hormone therapy-only group, (39.4 percent) than in the combined treatment group (29.6 percent), the researchers found.

Moreover, fewer men in the combined treatment group saw a return of their cancer (26 percent) than did men in the hormone-only group (75 percent).

The addition of local treatment with radiotherapy improves survival, Widmark concluded. "These patients are highly curable -- only 10 percent will die of prostate cancer within 10 years," he said. "They should not give up."

Dr. Chris Parker, from the Institute of Cancer Research in Sutton, Surrey, UK, and author of an accompanying editorial in the journal, said that combined radiation and hormone therapy should become standard treatment for men with locally advanced prostate cancer.

"This is a pivotal trial that for the first time demonstrates that radiotherapy improves survival of men with high-risk localized and locally advanced prostate cancer," Parker said. "It is no longer acceptable to regard hormone therapy alone as standard of care."

D'Amico agreed, noting that most U.S. doctors already provide combo therapy as standard treatment for men with locally advanced prostate cancer.

"Combined treatment with radiation and hormonal therapy is necessary to get the best overall survival in men with locally advanced prostate cancer," he said. "The study nails that home."

More information

For more information on prostate cancer, visit the American Cancer Society .

SOURCES: Anders Widmark, M.D., Ph.D., Department of Radiation Sciences, Oncology, Umeå University, Sweden; Chris Parker, M.D., Institute of Cancer Research, Sutton, Surrey, UK; Anthony D'Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women's Hospital, Boston; Dec. 16, 2008, online edition, The Lancet

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Angled gantry technique reduced breast radiation exposure by 50 percent
2. Preoperative radiation may improve survival rates in advanced rectal cancer patients
3. Delays in radiation therapy lead to increased breast cancer recurrence
4. Radiation before surgery improves pancreatic cancer outcomes
5. Mammogram most effective 12 months after radiation treatment
6. Type of breast reconstruction impacts radiation therapy outcomes
7. Partial Breast Irradiation Now Provided by Rocky Mountain Oncology Center
8. New model developed to estimate radiation skin doses during CT-guided interventional procedures
9. Premier Radiation Oncology Meeting Breaks Attendance, Exhibit Space Record at Boston Meeting
10. Radiation Oncology Experts from 16 Countries Attend Technical University of Munich's International Conference on TomoTherapy
11. Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers
Post Your Comments:
Related Image:
Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced ... franchise owner, Somu now offers travelers, value and care based Travel Services, including ... sales, as well as, cabin upgrades and special amenities such as, shore excursions, ...
(Date:11/26/2015)... ... , ... PRMA Plastic Surgery is updating their record books yet again with ... flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... it’s an honor to have served all of these women.” , PRMA is one ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology: